Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | DRD5 | P21918 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3066804 | 0.92 | HRH1 (0.56) | DRD2DRD1DRD4DRD5HRH1 | |
| SCHEMBL3053778 | 0.86 | MAPT (0.53) | DRD2DRD1DRD4DRD5HRH1 | |
| SCHEMBL12844288 | 0.85 | HRH1 (0.65) | DRD2DRD1DRD4DRD5HRH1 | |
| SCHEMBL12634482 | 0.85 | DRD2 (0.54) | DRD2DRD1DRD4DRD5HRH1 | |
| SCHEMBL74512 | 0.83 | PPARD (0.54) | — | |
| SCHEMBL73826 | 0.80 | CYP1A2 (0.52) | — | |
| SCHEMBL11254068 | 0.80 | HRH1 (0.63) | DRD2DRD1DRD4DRD5HRH1 | |
| SCHEMBL11259882 | 0.79 | HRH1 (0.57) | DRD2DRD1DRD4DRD5HRH1 | |
| SCHEMBL7293667 | 0.79 | MAPT (0.49) | DRD2DRD1 | |
| SCHEMBL3053018 | 0.79 | TAAR1 (0.61) | HRH1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101939326-B | Method for producing cycloplatinized platinum complexes, platinum complexes produced by said method, and the use thereof | RWTH AACHEN UNIVERSITY | 2013-06-05 | — | — | CN | disclosed |
| US-8394979-B2 | Process for preparing cycloplatinated platinum complexes, platinum complexes prepared by this process and the use thereof | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2013-03-12 | — | — | US | disclosed |
| CN-101939326-A | Method for producing cycloplatinized platinum complexes, platinum complexes produced by said method, and the use thereof | RWTH AACHEN | 2011-01-05 | — | — | CN | disclosed |
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | THPO, MCL1, PPOX | DRD2 4392/4885DRD1 4342/4885DRD4 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.